Stock info Boiron | Filter  Basic-Info

Boiron

The core activities of Boiron are in the pharmaceutical sector. Over the past 10 years the global pharmaceutical companies gained around 75 percent. Over the past 5 years the sector is 147 percent higher.

The past year gave good returns for Boiron investors

The stock gained over the past 12 months at around 6 percent. Boiron' stock rose the past 5 years at around 312 percent. Boiron's revenues between 2011 and 2015 were quite stable and moved between 566,58 million euros and 607,8 million euros. Boiron's net results between 2011 and 2015 were far from constant and moved between 42,26 million euros and 73,91 million euros.

Over the past 5 years the French company paid out dividends. Over the past 5 years Boiron's dividend yield was at around 5,8 percent per year.

Boiron financed with relatively low debt

As per the end of 2015 the French company's balance sheet equaled 695,45 million euros. The total debt was around 279,5 million euros. This is 40,19 percent of the total balance sheet. Last year the pharmaceutical company's price/earnings-ratio (PE) was around 17. So the investors valued the stock at 17 times 2015' earnings per share. We could say that based on it's price/earnings-ratio and dividend yield the French stock can be seen as a value stock.

At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the pharmaceutical company equaled around 1,37 billion euros. At the end of 2015 the French company had around 18,45 million stocks listed.

All the company's financial reports are available here. More information about Boiron can be found it's website. .